Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer

Regorafenib is an oral multi-kinase inhibitor used as salvage therapy for metastatic colorectal cancer (mCRC). We tested whether serum cytokine levels are associated with clinical outcome in the mCRC patients receiving regorafenib. Serum samples were collected before treatment start, day 21, and pro...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Suenaga, Mitsukuni, Mashima, Tetsuo, Kawata, Naomi, Wakatsuki, Takeru, Horiike, Yuki, Matsusaka, Satoshi, Dan, Shingo, Shinozaki, Eiji, Seimiya, Hiroyuki, Mizunuma, Nobuyuki, Yamaguchi, Kensei, Yamaguchi, Toshiharu
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085191/
https://ncbi.nlm.nih.gov/pubmed/27166185
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9187
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires